

References for the Tobacco Treatment Guide

1. Li W, Onyebeke C, Castro A, et al. *Summary of Vital Statistics, 2020*. Bureau of Vital Statistics, New York City Department of Health and Mental Hygiene; 2020. Accessed April 9, 2024. <https://www.nyc.gov/assets/doh/downloads/pdf/vs/2020sum.pdf>
2. New York City Department of Health and Mental Hygiene. EpiQuery — Community Health Survey, 2002-2013. Accessed April 9, 2024. <https://a816-health.nyc.gov/hdi/epiquery/visualizations?PageType=ps&PopulationSource=CHS>
3. RTI International. 2020 independent evaluation report of the New York Tobacco Control Program. December 2021. Accessed April 9, 2024. https://www.health.ny.gov/prevention/tobacco_control/docs/2020_independent_evaluation_report.pdf
4. U.S. Food and Drug Administration. Modifications to labeling of nicotine replacement therapy products for over-the-counter human use. Docket No. FDA-2013-N-0341. *Fed Reg*. April 2, 2013;78:19718-19721. Accessed April 9, 2024. <https://www.federalregister.gov/d/2013-07528>
5. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings. December 16, 2016. Accessed April 9, 2024. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-description-mental-health-side-effects-stop-smoking>
6. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): A double-blind, randomised, placebo-controlled clinical trial. *Lancet*. 2016;387(10037):2507-2520. doi:[10.1016/S0140-6736\(16\)30272-0](https://doi.org/10.1016/S0140-6736(16)30272-0)
7. Lindson N, Theodoulou A, Ordóñez-Mena JM, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: Component network meta-analyses. *Cochrane Database of Systematic Reviews*. 2023, issue 9. Art. no.: CD015226. doi:[10.1002/14651858.CD015226.pub2](https://doi.org/10.1002/14651858.CD015226.pub2)
8. Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. *Cochrane Database of Systematic Reviews* 2019, issue 4. Art. no.:CD013308. doi:[10.1002/14651858.CD013308.pub2](https://doi.org/10.1002/14651858.CD013308.pub2)
9. U.S. Department of Health and Human Services. *Smoking Cessation. A Report of the Surgeon General*. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2020. Accessed April 9, 2024. <https://www.hhs.gov/sites/default/files/2020-cessation-sgr-full-report.pdf>

10. Guo K, Wang S, Shang X, et al. The effect of varenicline and bupropion on smoking cessation: A network meta-analysis of 20 randomized controlled trials. *Addict Behav.* 2022;131:107329. doi:[10.1016/j.addbeh.2022.107329](https://doi.org/10.1016/j.addbeh.2022.107329)
11. Lindson N, Klemperer E, Hong B, Ordóñez-Mena JM, Aveyard P. Smoking reduction interventions for smoking cessation. *Cochrane Database of Systematic Reviews.* 2019, issue 9. Art. no.:CD013183. doi:[10.1002/14651858.CD013183.pub2](https://doi.org/10.1002/14651858.CD013183.pub2)
12. Rigotti NA, Kruse GR, Livingstone-Banks J, Hartmann-Boyce J. Treatment of tobacco smoking: A review. *JAMA.* 2022;327(6):566-577. doi:[10.1001/jama.2022.0395](https://doi.org/10.1001/jama.2022.0395)
13. Carpenter MJ, Wahlquist AE, Dahne J, et al. Nicotine replacement therapy sampling for smoking cessation within primary care: Results from a pragmatic cluster randomized clinical trial. *Addict.* 2020;115(7):1358-1367. doi:[10.1111/add.14953](https://doi.org/10.1111/add.14953)
14. Burriss JL, Heckman BW, Mathew AR, Carpenter MJ. A mechanistic test of nicotine replacement therapy sampling for smoking cessation induction. *Psychol Addict Behav.* 2015;29(2):392-399. doi:[10.1037/adb0000035](https://doi.org/10.1037/adb0000035)
15. Jardin BF, Cropsey KL, Wahlquist AE, et al. Evaluating the effect of access to free medication to quit smoking: A clinical trial testing the role of motivation. *Nicotine Tob Res.* 2014;16(7):992-999. doi:[10.1093/ntr/ntu025](https://doi.org/10.1093/ntr/ntu025)
16. Carpenter MJ, Hughes JR, Gray KM, Wahlquist AE, Saladin ME, Alberg AJ. Nicotine therapy sampling to induce quit attempts among smokers unmotivated to quit: A randomized clinical trial. *Arch Intern Med.* 2011;171(21):1901-1907. doi:[10.1001/archinternmed.2011.492](https://doi.org/10.1001/archinternmed.2011.492)
17. Dahne J, Wahlquist AE, Smith TT, Carpenter MJ. The differential impact of nicotine replacement therapy sampling on cessation outcomes across established tobacco disparities groups. *Prev Med.* 2020;136:106096. doi:[10.1016/j.ypmed.2020.106096](https://doi.org/10.1016/j.ypmed.2020.106096)